Bio-Rad Laboratories Inc (BIO-B) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Bio-Rad Laboratories Inc stock (BIO-B) is currently trading at $268.55. Bio-Rad Laboratories Inc PS ratio (Price-to-Sales) is 2.61. WallStSmart rates BIO-B as Sell.
- BIO-B PE ratio analysis and historical PE chart
- BIO-B PS ratio (Price-to-Sales) history and trend
- BIO-B intrinsic value — DCF, Graham Number, EPV models
- BIO-B stock price prediction 2025 2026 2027 2028 2029 2030
- BIO-B fair value vs current price
- BIO-B insider transactions and insider buying
- Is BIO-B undervalued or overvalued?
- Bio-Rad Laboratories Inc financial analysis — revenue, earnings, cash flow
- BIO-B Piotroski F-Score and Altman Z-Score
- BIO-B analyst price target and Smart Rating
Bio-Rad Laboratories Inc
📊 No data available
Try selecting a different time range
Smart Analysis
Bio-Rad Laboratories Inc (BIO-B) · 10 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in peg ratio, price/book. Concerns around return on equity and operating margin. Mixed signals suggest waiting for clearer direction before acting.
Bio-Rad Laboratories Inc (BIO-B) Key Strengths (3)
Trading below book value, meaning the market prices it less than net assets
Good growth relative to its price
Mid-cap company balancing growth potential with stability
Supporting Valuation Data
Bio-Rad Laboratories Inc (BIO-B) Areas to Watch (7)
Company is destroying shareholder value
Revenue declining -4.20%, a shrinking business
Earnings declining -83.00%, profits shrinking
Company is losing money with a negative profit margin
Very thin margins with limited operational efficiency
Very low institutional interest at 0.06%
Revenue is fairly priced at 2.61x sales
Supporting Valuation Data
Bio-Rad Laboratories Inc (BIO-B) Detailed Analysis Report
Overall Assessment
This company scores 37/100 in our Smart Analysis, earning a F grade. Out of 10 metrics analyzed, 3 register as strengths (avg 8.3/10) while 7 fall into concern territory (avg 1.4/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Price/Book, PEG Ratio, Market Cap. Valuation metrics including PEG Ratio (1.21), Price/Book (0.95) suggest the stock is attractively priced.
The Bear Case
The primary concerns are Return on Equity, Revenue Growth, EPS Growth. Some valuation metrics including Price/Sales (2.61) suggest expensive pricing. Growth concerns include Revenue Growth at -4.20%, EPS Growth at -83.00%, which may limit upside. Profitability pressure is visible in Return on Equity at -27.50%, Operating Margin at 9.72%, Profit Margin at -85.20%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -27.50% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at -4.20% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Revenue Growth are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
BIO-B Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
BIO-B's Price-to-Sales ratio of 2.61x sits near its historical average of 2.61x (0th percentile), suggesting the market is pricing in steady-state growth. The current valuation is 0% below its historical high of 2.61x set in Feb 2026, and 0% above its historical low of 2.61x in Feb 2026.
WallStSmart Analysis Synopsis
Data-driven financial summary for Bio-Rad Laboratories Inc (BIO-B) · HEALTHCARE › MEDICAL DEVICES
The Big Picture
Bio-Rad Laboratories Inc is in a turnaround phase, with management focused on restoring profitability. Revenue reached 2.5B with 420% decline year-over-year. The company is currently unprofitable, posting a -85.2% profit margin.
Key Findings
Generating 71M in free cash flow and 117M in operating cash flow. Earnings are translating into actual cash generation.
Debt-to-equity ratio of 0.20 indicates a conservative balance sheet with 369M in cash.
Revenue contracted 420% YoY. Worth determining whether this is cyclical or structural.
The company is unprofitable with a -85.2% profit margin. The path to breakeven will be the key catalyst.
What to Watch Next
Debt management: total debt of 1.4B is significantly higher than cash (369M). Monitor refinancing risk.
Sector dynamics: monitor MEDICAL DEVICES industry trends, competitive moves, and regulatory changes that could impact Bio-Rad Laboratories Inc.
Bottom Line
Bio-Rad Laboratories Inc is in turnaround mode. The path to profitability remains the critical question. Speculative investors may see opportunity in the recovery story, but conservative investors should wait for consistent positive earnings before committing capital.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions(0 last 3 months)
Data sourced from SEC Form 4 filings
Last updated: 8:27:45 AM
About Bio-Rad Laboratories Inc(BIO-B)
NYSE
HEALTHCARE
MEDICAL DEVICES
USA
Bio-Rad Laboratories, Inc. is an American developer and manufacturer of specialized technological products for the life science research and clinical diagnostics markets.